Search

Novo Nordisk A-S (Class B)

Chiusa

341.35 -0.28

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

340.8

Massimo

343.3

Metriche Chiave

By Trading Economics

Entrata

-2.5B

27B

Vendite

-1.2B

77B

P/E

Media del settore

14.432

37.461

EPS

5.96

Rendimento da dividendi

3.4

Margine di Profitto

34.484

Dipendenti

78,387

EBITDA

44B

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+9.53% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

3.40%

2.33%

Utili prossimi

5 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

138B

1.5T

Apertura precedente

341.63

Chiusura precedente

341.35

Novo Nordisk A-S (Class B) Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

17 ott 2025, 10:26 UTC

I principali Market Mover

Ozempic Maker Novo Nordisk Shares Fall as Trump Moves to Cut Price of Weight-Loss Drugs

17 ott 2025, 10:25 UTC

I principali Market Mover

Ozempic Maker Novo Nordisk Shares Fall as Trump Moves to Cut Price of Weight-Loss Drugs

15 ott 2025, 15:36 UTC

Acquisizioni, Fusioni, Takeovers

Novo Nordisk to Buy Blood Disease Drug From Omeros for Up to $2.1 Billion -- Update

15 ott 2025, 13:27 UTC

Acquisizioni, Fusioni, Takeovers

Novo Nordisk to Pay Omeros Up to $2.1 Billion for Blood Disease Drug

9 ott 2025, 10:49 UTC

Acquisizioni, Fusioni, Takeovers

Novo Nordisk to Acquire Akero Therapeutics for Up to $5.2 Billion

1 ott 2025, 08:54 UTC

I principali Market Mover

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

22 ott 2025, 10:45 UTC

Utili

AI Stocks Aren't the Only Market Play. How -2-

22 ott 2025, 10:45 UTC

Utili

AI Stocks Aren't the Only Market Play. How Earnings Are Easing Recession Fears. -- Barrons.com

17 ott 2025, 10:10 UTC

I principali Market Mover

Ozempic Maker Novo Nordisk Shares Fall as Trump Moves to Cut Price of Weight-Loss Drugs

15 ott 2025, 12:33 UTC

Acquisizioni, Fusioni, Takeovers

Novo Nordisk: Omeros Could Recieve Up to Total of $2.1B Including Potential Milestones, Tiered Royalties

15 ott 2025, 12:32 UTC

Acquisizioni, Fusioni, Takeovers

Novo Nordisk: Omeros Eligible to Receive $340M in Upfront and Near-Term Milestone Payments

15 ott 2025, 12:32 UTC

Acquisizioni, Fusioni, Takeovers

Novo Nordisk Will Be Granted Exclusive Global Rights to Develop, Commercialise Zaltenibart in All Indications

15 ott 2025, 12:32 UTC

Acquisizioni, Fusioni, Takeovers

Novo Nordisk, Omeros in Asset Purchase and License Pact for Omeros' Rare Blood and Kidney Disorder Drug

10 ott 2025, 16:19 UTC

Acquisizioni, Fusioni, Takeovers

Bristol Myers Squibb Buys Private Biotech for $1.5 Billion. The Deal Wave Keeps Going. -- Barrons.com

10 ott 2025, 13:03 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Novo Nordisk's Akero Deal Makes Sense But Raises Questions -- Market Talk

9 ott 2025, 15:17 UTC

Acquisizioni, Fusioni, Takeovers

Novo Nordisk Is Buying Akero Therapeutics. It's More Good News for Biotech Stocks. -- Barrons.com

9 ott 2025, 11:31 UTC

Acquisizioni, Fusioni, Takeovers

Akero Therapeutics Stock Soars. Novo Nordisk Is Buying the Biotech for up to $5.2 Billion. -- Barrons.com

9 ott 2025, 10:34 UTC

Acquisizioni, Fusioni, Takeovers

Novo Nordisk to Acquire Akero Therapeutics for Up to $5.2B

9 ott 2025, 10:07 UTC

Acquisizioni, Fusioni, Takeovers

Novo Nordisk Says Metabolic Dysfunction-Associated Steatohepatitis is Closely Linked With Diabetes and Obesity

9 ott 2025, 10:05 UTC

Acquisizioni, Fusioni, Takeovers

Novo Nordisk: Akero is Developing Treatment For Liver Disease Metabolic Dysfunction-Associated Steatohepatitis

9 ott 2025, 10:04 UTC

Acquisizioni, Fusioni, Takeovers

Akero: Each CVR to Entitle Holder to Cash Payment of $6/Shr Upon Full U.S. Regulatory Approval of Efruxifermin for Treatment of Compensated Cirrhosis Due to MASH by June 30, 2031 >AKRO

9 ott 2025, 10:03 UTC

Acquisizioni, Fusioni, Takeovers

Novo Nordisk To Buy Akero Therapeutics for $4.7B in Cash, Plus Potentially an Additional $500M

9 ott 2025, 10:01 UTC

Acquisizioni, Fusioni, Takeovers

Novo Nordisk Agrees to Buy Akero Therapeutics For $54 a Share

7 ott 2025, 09:15 UTC

Discorsi di Mercato

Novo Nordisk Consensus 2027 Sales Expectations Look Too High -- Market Talk

1 ott 2025, 09:05 UTC

Azioni calde

Stocks to Watch Wednesday: Nike, Lithium Americas, Arm, Occidental -- WSJ

29 set 2025, 12:04 UTC

Discorsi di Mercato

Novo Nordisk Faces Headwind as U.S Obesity Drugs Stall, Competition Rises -- Market Talk

22 set 2025, 13:43 UTC

Acquisizioni, Fusioni, Takeovers

Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion -- Update

18 set 2025, 12:30 UTC

Discorsi di Mercato

Correction to Novo Nordisk Market Talk

18 set 2025, 12:00 UTC

Discorsi di Mercato

Novo Nordisk's Prospects Could Turn Around -- Market Talk

18 set 2025, 08:55 UTC

Azioni calde

Stocks to Watch Thursday: Nvidia, PayPal, Novo Nordisk -- WSJ

Novo Nordisk A-S (Class B) Previsione

Obiettivo di Prezzo

By TipRanks

9.53% in crescita

Previsioni per 12 mesi

Media 1,162.73 DKK  9.53%

Alto 1,550 DKK

Basso 720 DKK

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Novo Nordisk A-S (Class B) - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

11 ratings

7

Acquista

2

Mantieni

2

Vendi

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Novo Nordisk A-S (Class B)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
help-icon Live chat